{"entity":{"id":"nct07604285","kind":"trial","name":"A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma","aka":[],"tldr":"A phase 1/2 trial of MT-125 run by Myosin Therapeutics Inc., not yet recruiting.","summary":"A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma is a phase 1/2 interventional study registered as NCT07604285 by Myosin Therapeutics Inc., with 36 participants planned, started 2026-07. Conditions recorded: Glioblastoma. Interventions recorded: MT-125.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07604285","url":"https://clinicaltrials.gov/study/NCT07604285"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["mt-125"],"companies":["myosin-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07604285","phase":"1/2","setting":"A Phase 1/2 Dose Escalation and Randomized Expansion Study of Safety, Tolerability, and Pharmacokinetics of MT-125 Monotherapy With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma","sponsor":"Myosin Therapeutics Inc.","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07604285/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"mt-125","kind":"drug","name":"MT-125","route":"/drugs/mt-125/"}],"company":[{"id":"myosin-therapeutics","kind":"company","name":"Myosin Therapeutics","route":"/companies/myosin-therapeutics/"}]}}